⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

ONESOURCE - Technical Analysis with Chart Patterns & Indicators

← Back to List

⭐ Rating: 3

Last Updated Time : 02 Aug 26, 04:09 pm

Key Parameters

⭐ Technical Rating: 3.0

Stock CodeONESOURCE
Market Cap18,622 Cr.
Current Price1,620 ₹
High / Low1,990 ₹
Stock P/E351
Book Value519 ₹
Dividend Yield0.00 %
ROCE2.06 %
ROE0.45 %
Face Value1.00 ₹
DMA 501,666 ₹
DMA 2001,648 ₹
Chg in FII Hold1.69 %
Chg in DII Hold2.76 %
PAT Qtr51.2 Cr.
PAT Prev Qtr19.8 Cr.
RSI43.6
MACD5.57
Volume4,49,480
Avg Vol 1Wk3,94,908
Low price1,057 ₹
High price1,990 ₹
PEG Ratio13.1
Debt to equity0.25
52w Index60.3 %
Qtr Profit Var106 %
EPS4.15 ₹
Industry PE33.6

✅ Positive

The stock has shown a strong rebound in the most recent quarter with PAT increasing by 106%, indicating improved profitability. Additionally, FII holding is up and DII holdings are also rising, suggesting growing investor confidence.

⚠️ Limitation

Despite earnings growth, the high P/E ratio of 351 and PEG ratio of 13.1 suggest the stock may be overvalued relative to its earnings potential. The recent executive resignation could raise concerns about company stability.

📉 Company Negative News

Analysts are updating their estimates following Q1 results, implying potential downward revisions if future performance doesn’t meet expectations. The appointment of a new HR head alongside a key executive's resignation highlights internal restructuring and could introduce operational uncertainty.

📈 Company Positive News

None found

🏭 Industry

The specialty pharma industry is currently experiencing growth driven by aging populations and increasing demand for specialized medications, though it remains sensitive to regulatory changes and competition from larger pharmaceutical firms. Companies within this sector often demonstrate volatility due to patent expirations and the complexities of drug development.

🧾 Conclusion

Based on the chart patterns, the stock is trading in a consolidation phase with the 50-DMA slightly above the 200-DMA, suggesting potential upward momentum if it breaks through the resistance at 1990₹. A short-term entry zone could be established between 1,600₹ and 1,680₹ targeting the resistance level. An exit strategy would involve setting a stop-loss order around 1,580₹ or triggering a sell signal if the price breaks below the 1,648₹ DMA. Overall, while promising in the short term, further investigation is warranted considering the valuation and recent management changes.

Technical Analysis
Fundamental Analysis

NIFTY 50 · Technical

NEXT 50 · Technical

MIDCAP · Technical

SMALLCAP · Technical